Patients’ ( fig 2B ) and physicians’ median global assessment scores showed a trend towards “feeling well” from the placebo run-in to the end of active treatment (week 8) and shifted back towards “feeling very unwell” during the post-treatment follow-up phase.
← all excerpts
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
1
—
—